Docetaxel as single-agent first-line treatment for advanced non-small cell lung cancer
-
摘要: 目的 探讨多西他赛单药一线治疗晚期非小细胞肺癌临床疗效及不良反应.方法 48例晚期非小细胞肺癌患者,多西他赛75 mg/m2静脉滴注,第1天.21 d为1个周期,治疗2～4个周期后评价临床疗效及不良反应.结果 48例患者共化疗140个周期,中位化疗2.9个周期.RR为25.0％,DCR为56.3％,中位无进展生存期5.3个月,中位生存期8.6个月,1年生存率35.4％.不良反应以粒细胞减少、贫血、腹泻、脱发为主.结论 多西他赛单药一线治疗晚期非小细胞肺癌临床疗效良好,患者耐受性较好.
-
-
赖寒. DP方案与GP方案治疗非小细胞肺癌的临床观察 [J]. 遵义医学院学报, 2011(1):49.doi: 10.3969/j.issn.1000-2715.2011.01.018. 吴峰, 孟春艳. 多西他赛治疗老年晚期非小细胞肺癌的临床观察 [J]. 中医临床研究, 2011(3):40.doi: 10.3969/j.issn.1674-7860.2011.03.023. Song Z, Yu Y, Chen Z. Third-line therapy for advanced non-small-cell lung cancer patients:feasible drugs for feasible patients [J]. Mcd Oncol, 2011(1):605. Dagli A F, Uer O. Cytopathologic features of pleomorphic carcinoma of the lung:case report [J]. Turk Patoloji Derg, 2012(1):72. Bonomi M, Pilotto S, Milella M. Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer:Future Perspectives For Clinical Research[ [J]. Journal of Experimental & Clinical Cancer Research, 2011(1):115. Jinturkar K A, Anish C, Kumar M K. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines [J]. Biomaterials, 2011. Terashima T, Matsuzaki T, Ogawa R. Concurrent Chemoradiotherapy with Carboplatin and Docetaxel for Stage Ⅲ Non-Small Cell Lung Cancer [J]. Gan to Kagaku Ryoho(Japanese Journal of Cancer and Chemotherapy), 2011, (13):2585. Cromwell I, van der Hoek K, Melosky B. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer:a real-world cost-effectiveness analysis [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, (12):2097. Ackert U, Haffner D, Classen C F. Non-small cell lung carcinoma in an adolescent manifested by acute paraplegia due to spinal metastases:a case report [J]. J Med Case Reports, 2011(1):486.
计量
- 文章访问数: 113
- HTML全文浏览量: 22
- PDF下载量: 4
下载:
苏公网安备 32100302010246号
